Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Mainz Biomed NV (MYNZ) had Stock-Based Compensation of $1.03M for the most recently reported fiscal quarter, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$2.39M |
|
$1.63M |
|
$6.06M |
|
$8.45M |
|
$10.01M |
|
$1.05M |
|
$2.58M |
|
$12.59M |
|
$-4.14M |
|
$-7.34M |
|
$-4.14M |
|
25.59M |
|
| Cash Flow Statement Financials | |
$-8.14M |
|
$-0.42M |
|
$2.55M |
|
$7.07M |
|
$0.98M |
|
$-6.09M |
|
|
Stock-Based Compensation |
$1.03M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|